Abstract
By examining experience with evaluation of licensed vaccines we theorize that a critical level of serum IgG confers protection against infectious diseases by killing or inactivating the inoculum. We found that efficacy is reliably predicted by measurement of serum antibodies elicited by vaccines, that serum IgG antibodies alone account for the protection conferred by passive immunization, that vaccine-induced “herd” immunity is best explained by inactivation of the inoculum on epithelial surfaces by serum antibodies and that serum antibodies induced by active immunization will neither treat disease symptoms nor eliminate the pathogen. If valid, this theory should facilitate research because knowledge of the pathogenesis of the disease symptoms may not be essential for vaccine development.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Ad Hoc Group for the study of pertussis vaccines. Placebo-controlled trial of two acellular pertussis vaccines in Sweden-protective efficacy and adverse events. Lancet i:955–960.
Alexander H.E. Experimental basis for treatment of Haemophilus influenzae infections. Amer. J. Dis. Child. 1943:66:160–71.
Andersson M., Carlin N, Leontein K, Lindquist U, Slettengren K. Structural studies of the O-antigenic polysaccharide of Escherichia coli O86, which possess blood-group B activity. Carbohydr. Res. 1989:185:211–23.
Anderson P. Antibody responses to Haemophilus influenzae type b and diphtheria toxin induced by conjugates of oligosaccharides of the type b capsule with the nontoxic protein CRM 197. Infect. Immun. 1983:39:233–8.
Austrian R. Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention. Rev. Infect. Dis. Suppl: 1981:S1-S17
Baker CJ, Kasper DL. Correlation of maternal antibody deficiency and susceptibility to neonatal group B streptococcal infection. N. Eng. J. Med. 294:753–756.
Batty I, Bullen JJ. The permeability of the sheep and rabbit intestinal wall to antitoxin present in the circulation. J. Path. Bact. 1961:81:447–58.
Beasley RP, Hwang L-Y, Steven CE, et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: Final report of a randomized double-blind, placebo-controlled trial. Hepatology. 1983:3:135–41.
Bellamy JEC, Ole Nielsen N. Immune-mediated emigration of neutrophils into the lumen of the small intestine. 1974:9:615–19.
Bellanti JA. Biologic significance of the secretory yA immunoglobulins. Pediatr. 1975:48:715–29.
Benenson AS. Review of experience with whole-cell and somatic antigen vaccines. Proceedings of the 12th Joint Conference of US Japan Cooperative Medical Sciences Program, Cholera Panel, Sapporo. 1976:228-42.
Black SB, Shinefield HR, and the Kaiser Permanente Vaccine Study Group. Pediatr. Infect. Dis. J. 1992:11:610–13.
Blaser MJ. Newman LS. A review of human salmonellosis: Infective dose. Rev. Infect. Dis. 1982:4:1096–106.
Böttiger M. Long-term immunity following vaccination with killed poliovirus vaccine in Sweden, a country with no circulating virus. Rev. Infect. Dis. 1984:6:S548–S51.
Bouvet JP, Bélec L, René Pirès, Pilot J. Immunoglobulin G antibodies in human vaginal secretions after parenteral vaccination. Infect. Immun. 1994:62:3957–61
Bruss JB, Siber G. Treatment of severe pertussis with intravenous pertussis immune globulin. Abstract ICCAAC 103761.1993.
Bruton OC. Agammaglobulinemia. Pediatr. 1952:9:727–8.
Carlin NIA, Svenson SB, Lindberg AA. Role of monoclonal 0-antigen antibody epitope specificity and isotype in protection against experimental mouse typhoid. Microbiol. Path. 1987:2:171–183130.
Centers for Disease Control. General Recommendations on Immunization. MMWR. 1994:43:RR–1.
Centers for Disease Control. Inactivated Japanese Encephalitis Virus Vaccine. MMWR, 1993:42:RR–1.
Centers for Disease Control. Pertussis vaccination: Acellular pertussis vaccine for reinforcing and booster use-Supplementary ACIP Statement. MMWR. 1992:41:1–10.
Centers for Disease Control. Rubella Prevention. MMWR, 1981:3037–47
Chanock RM, Crowe JE Jr, Murphy BR, Burton DR. Human monoclonal antibody Fab fragments cloned from combinatorial libraries: Potential usefulness in prevention and.or treatment of major human viral diseases. Infect. Agents Dis. 1993:2:118–31.
Chodriker WB, Tornasi TB Jr. Gamma globulins: quantitative relationship in human sera and non-vascular fluids. Science 1963:142:1080–81.
Chu CY, Schneerson R, Robbins JB, Rastogi SC. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect. Immun. 1983:40:245–56.
Clemens JD, Sack DA, Chakraborty J. et al. Field trial of oral cholera vaccines in Bangladesh: Evaluation of anti-bacterial and anti-toxic breast-milk immunity in response to ingestion of the vaccines. Vaccine 1990:8:469–72.
Clemens JD, Sack DA, Harris JR, et al. Field trial of oral cholera vaccines in Bangladesh: results from a three-year follow-up. Lancet 1990:335:270–73.
Cohen D, Ashkenazi S, Green M. et al. Safety and immunogenicity of Shigella flexneri 2a and Shigella sonnei conjugate vaccines: preliminary efficacy of the S. sonnei conjugate in Israeli soldiers, submitted for publication. 1994.
Cohen D, Green MS, Block C., Slepon R, Ofek I. A prospective study on the association between serum antibodies to lipopolysaccharide and attack rate of shigellosis. J. Clin. Microbiol. 1991:29:386–9.
Conley AJ, Gorny MK, Kessler JA II. et al. Neutralization of pimrary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J. Virol. 1994:68:6994–7000.
Douglas RM, Hansman D, Miles HB, Paton JC. Pneumococcal carriage and type-specific antibody. Failure of a 14-valent vaccine to reduce carriage in healthy children. Am. J. Dis. Child. 1986:140:1183–5.
DuPont HL, Levine MM, Hornick RB, Formal SB. Inoculum size in shigellosis and implications for expected mode of transmission. J. Infect. Dis. 1989:159:1126–28.
Eibl MM, Cairns L, Rosen FS. Safety and efficacy of a monomeric, functionally intact intravenous IgG preparation in patients with primary immunodeficiency syndromes. Clin. Imunol. Immunopathol. 1994:31:151–69.
Faden H, Modlin JF, Thomas ML, McBean AM, Ferdon MB, Ogra P.L. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated poliovirus vaccines in childhood: Systemic and local immune responses. J. Infect. Dis. 1990:162:1291–97.
Ferreccio C., Prado V, Ojeda A, Cayyazo M., Abrego P, Guers L, Levine MM. Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile. Amer. J. Epid. 1991:134:614–27.
Fine PEM, Clarkson J. Measles in England and Wales III: Assessing published predictions of the impact of vaccination on incidence. Int. J. Epidemiol. 1983:12:332–39.
Floyd TM, Higgins AR, Kader MA. Studies in shigellosis. V. The relationship of age to the incidence of Shigella infections in Egyptian children, with special reference to shigellosis in the newborn and in infants in the first six months of life. Amer. J. Trop. Med. 1956:5:119–30.
Fothergill LD, Wright J. Influenzai meningitis: relation of age incidence to the bactericidal power of blood against the causal organism. J. Immunol. 1993:24:273–84.
Fulginiti VA, Eller JJ, Donnei AW, Kempe CH. Altered reactivity to measles virus: atypical measles in children previously immunized with inactivated virus vaccines. JAMA. 1967:202:1075.
Gaines S, Currie JA, Tully JG. Production of incomplete Vi antibody in man by typhoid vaccine. Amer. J. Epid. 1965:81:350–5.
Gershon A, Steinberg SP, The National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. Live attenuated varicella vaccine: Protection in healthy adults compared with leukemic children. J. Infect. Dis. 1990:161:661–66.
Glezen WP, Lamb GA, Beiden EA, Chin TDY. Quantitative relationship of preexisting homotypic antibodies to the excretion of attenuated poliovirus type 1. Am. J. Epidemiol. 1968:83:224–37.
Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 1969:129:1307–26
Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state. J. Exp. Med. 1969:129:1385–95.
Granstrom M., Olinder-Nielsen AM, Holmbad P, Marks A, Hanngren K. Specific immunoglobulin for treatment of whooping cough. Lancet. 1991:33:1230–2.
Gren KY, Taniguchi K, Mackow ER, Kapikian AZ. Homotypic and heterotypic epitope-specific antibody responses in adult and infant rotavirus vaccinees: implications for vaccine development. J. Infect. Dis. 1990:161:667–79.
Groothuis JR, Simoes EAF, Levin MJ. et al. Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High Risk Infants and Young Children. N. Engl. J. Med. 1993:329:1524–1527.
Guirgis N, Schneerson R, Bax A, Egan W, Robbins JB, Shiloach J, Ørskov I, Ørskov F. Escherichia coli K51 and K93 capsular polysaccharides cross-reactive with Group A meningococcal polysaccharide. J. Exp. Med. 1985:162:1837–51.
Gupta RK, Robbins JB, Szu SC. Comparative immunogenicity of conjugates composed of Escherichia coli O111 O-specific polysaccharide prepared by treatment with acetic acid or hydrazine and bound to tetanus toxoid by two synthetic schemes. Infect. Immun. in press. 1995.
Hambleton P, Turnbull RCB. Anthrax vaccine development: a continuing story. In Bacterial Vaccines, Eds F.A. Liss, Inc. New York, NY 1990:105–22
Isacson J, Trollfors B, Taranger J, MacDowell I, Johansson J, Lagergård T, Robbins JB. Safety, immunogenicity and an open, retrospective study of efficacy of a monocomponent pertussis toxoid vaccine in infants. Pediatr. Infect. Dis. 1993:13:22–7.
Janeway CA, Rosen FS, Merler E, Alper CA. The gamma globulins. Little, Brown & Co., Boston. 1967.
Kampelbacher EH. On antigenic 0-relationships between the Groups Salmonella, Arizona, Escherichia and Shigella, Antonie van Leeuwenhoek J. Micro. Serol. 1984:25:289–324.
Katz MA, Landesman SH, Schiffman G. A comparison of antibody concentration measured by mouse protection assay and radioimmunoassay in sera from patients at high risk of developing pneumococcal disease. Mol. Immunol. 1984:21:1061–65.
Konadu E, Robbins JB, Shiloach J, Bryla DA, Szu SC. Preparation, characterization and immunological properties in mice of Escherichia coli O157 O-specific polysaccharide-protein conjugate vaccines. Infect. Immun. 1994:62:5048–54.
Krugman S, Giles JP, Friedman H, Stone S. Studies on immunity to measles. J. Pediatr. 1965:66:471–88.
Levine MM, Ferreccio C., Black RE, Germanier R. Chilean Typhoid Committee. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet, 1987:i: 1049–52.
Levine MM. Immunity to cholera as evaluated in volunteers. Cholera and Related Diarrheas. 43rd Nobel Symposium. Stockholm 1978. Karger, Basel. Eds. O. Ouchterlony and J. Holmgren. 1980:195-203.
Levine MM, Tacket CO. Recombinant live cholera vaccines. In Vibrio cholerae and Cholera. Molecular to Global Perspectives. Eds. I.K. Wachsmuth, P.A. Blake, Orjan Olsvik. American Society for Microbiology, Washington, DC. 1994:395–414
Lindberg AA, Haeggman S, Karlsson K, Dac Cam P, Du Trach D. The humoral antibody response to Shigella dysenteriae type 1 as determined by ELISA. Bull. W.H.O. 1984:62:597–606.
MacLeod CM, Hodges RG, Heidelberger M., Bernhard WG. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J. Exp. Med. 1945:82:445–65.
Mäkela PH, Herva E, Sibakov M., Henrichsen J, Luotonen J, Leinonen M., Timonen M., Koskela M., Pukander J, Gronroos P, Pontynen S, Karma P. Pneumococcal vaccine and otitis media. Lancet 1980:ii:547–51.
Meade BD, Kind PD, Manclark CR. Lymphocytosis-promoting factor of Bordetella pertussis alters mononuclear phagocyte circulation and response to inflammation. Infect. Immun. 1984:46:733–39.
Mosley WH. The role of immunity in cholera: A review of epidemiology and serological studies. Tex. Rep. Biol. Med. 1969:27:227–41.
Mosley WH, Woodward WE, Aziz KMA, Rahman ASMM, Chowdhury AKMA, Ahmed A, Feely JC. The 1968–1969 cholera-vaccine field trial in rural East Pakistan. Effectiveness of monovalent Ogawa and Inaba vaccines and a purified Inaba antigen, with comparative results of serological and animal protection tests. J. Infect. Dis. 1970:121:S1–S9.
Moxon R, Murphy PA. Haemophilus influenzae bacteremia and meningitis resulting from the survival of a single organism. Proc Natl Acad Sci USA. 1978:75:1534–6.
Neoh SH, Rowley D. The antigens of Vibrio cholerae involved in the vibriocidal action of antibody and complement. J. Infect. Dis. 1970:121:505–13.
Norrby E, Penttiten K. Differences in antibody to the surface components of measles after immunization with formalin-inactivated and live virus vaccines. J. Infect. Dis. 1978:138:672–80.
Ogra PL, Karson DT, Righthand R, MacGillivray M. Immunoglobulin response in serum and secretions after immunization with live and inactivated poliovaccine and natural infection. N. Eng. J. Med. 1968:279:883–900.
Orskov I, Orskov F, Jann B, Jann K. et al. Serology, chemistry, and genetics of 0 and K antigens in Escherichia coli. Bact. Rev. 1977:41:667–710.
Pappenheimer AM Jr. Diphtheria. In Bacterial Vaccines. Ed. Rene Germanier. Academic Press, NY, 1984:1–32.
Pappenheimer AM, Murphy JR. Studies on the molecular epidemiology of diphtheria. Lancet. 1983:2:923–25.
Peltola H, Mäkelä PH, Elo O, Pettay O, Renkonen OV, Sivonen A. Vaccination against meningococcal Group A disease in Finland 194–75. Scand. J. Infect. Dis. 1976:8:169–74.
Pierce NF, Reynolds HY. Immunity to experimental cholera. I. Protective effect of humoral IgG antitoxin demonstrated by passive immunization. J. Immunol. 1974: 113:1017–23.
Pittman M. Pertussis toxin: The cause of the harmful effects and prolonged immunity of whooping cough. A hypothesis. Rev. Infect. Dis. 1979:1:401–412
Prince GA, Horswood RK, Chanock RM. et al. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J. Virol. 1985:55:517–20.
Provost PJ, Hilleman MR. Propogation of human hepatitis A virus in cell culture in vitro Proc Soc Exp Biol. Med. 1978:160:213–21.
1994 Redbook. Report of the Committee on Infectious Diseases. 1994. 23rd Edition, American Academy of Pediatrics, Rabies. 1994:383-95.
Redbook. Report of the Committee on Infectious Diseases. 1994. 23rd Ed, American Academy of Pediatrics, Tetanus, 1994:458-63.
Reynolds H, Thompson RE. Pulmonary host defenses. I. Analysis of protein and lipids in bronchial secretions and antibody responses after vaccination with Pseudomonas aeruginosa, J. Immunol. 1973:111:358–68.
Robbins JB, Chu CY, Schneerson R. Hypothesis for vaccine development: Protective immunity to enteric diseases caused by nontyphoidal Salmonellae and Shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides. Clin. Infect. Dis. 1992:15:346–361
Robbins JB, Parke JC, Schneerson R, Whisnant JK. Quantitative measurement of “natural” and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediat. Res. 1973:7:103–10.
Robbins JB, Pittman M., Trollfors B, Lagergård TA, Taranger J, Schneerson R. Primum non nocere: a pharmacologically inert pertussis toxoid alone should be the next pertussis vaccine. Pediatr. Infect. Dis. 1993:12:795–807.
Robbins, J.B., R. Schneerson and S.C. Szu. 1995. Persepctive: Hypothesis: Serum IgG antibody is suficient to confer protection against infectious diseases by inactivating the inoclum. J. Infect. Dis. 171: in press
Robbins JB, Schneerson R, Glode MP, Vann WF, Schiffer MS, Liu T-Y, Parke JC Jr. Huntley C. Cross-reactive antigens and immunity to diseases caused by encapsulated bacteria. J. All. Clin. Immunol. 1975:56:141–51.
Robbins JB, Schneerson R. Polysaccharide-protein conjugates: A new generation of vaccines. J. Infect. Dis. 1990:161:821–32.
Robbins JB. Towards a new vaccine for pertussis. In: Schlesinger, J., ed., Microbiology. Washington, DC: American Society for Microbiology, 1994:176–83.
Robbins JD, Robbins JB. Re-examination of the immunopathogenic role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. J. Infect. Dis. 1984: 47:436–99.
Salk D. Herd effect and virus eradication with use of killed poliovirus vaccine. Eds. W. van Henessenn. Develop. Biol. Stand. 1981:47:247-55.
Sato H, Sato Y. Bordetella pertussis infection in mice: correlation of specific antibodies against two antigen, pertussis toxin and filamentous hemagglutinin with mouse protective activity in an intracerebral or aerosol challenge system. Infect. Immun. 1984:46:415–21.
Sato Y, Ito A, Chiba J, Sato Y. Monoclonal antibody against pertussis toxin: Effect on toxin activity and pertussis infection. Infect. Immun. 1994:46:422–28.
Schneerson R, Barrera O, Sutton A, Robbins JB. Preparation, characterization and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J. Exp. Med. 1980:152:361–76.
Sellwood R, Hall G, Anger H. et al. Emigration of polymorphonuclear leucocytes in to the intestinal lumen of the neonatal piglet in response to challenge with K88-positive Escherichia coli. Res. Veter. Sci. 1986:40:128–35.
Shurin PA, Rehmus JM, Johnson CE. et al. Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high-risk children. J. Pediatr. 1993:123:801–10.
Smith DH, Peter G, Ingram DL, Anderson P. Responses of children immunized with the capsular polysaccharide of Haemophilus influenzae type b. Pediatrics. 1975:52:637–41.
Springer GF, Horton RE, Forbes M. et al. Origin of anti-human blood group B agglutinins in white leghorn chicks. J. Exp. Med. 1959:110:221–44.
Sutter RW, PA Patriarca. Inactivated and live atttenuated poliovirus vaccines: mucosal immunity. In: Kurstak E. ed. Measles and poliomyelitis. Vaccines and immunisation. New York: Springer Verlag, 1993.
Syndman DR, Werner BG, Heinze-Lacey B. et al. Use of cytomegalovirus globulin to prevent cytomegalovirus disease in renal tranplant recipients. N. Eng. J. Med. 1987:317:1049–54.
Szu SC, Gupta RK, Robbins JB. Induction of serum vibriocidal antibodies by O-specific polysaccharideprotein conjugate vaccines for prevention of cholera. In Vibrio cholerae and Cholera. Molecular to Global Perspectives. Eds, Wachsmuth IK, Blake PA, Olsvik O. Washington, DC: American Society for Microbiology. 1994:381–94.
Szu SC, Taylor DN, Trofa AC, et al. Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines Infect. Immun. in press. 1994.
Takala AK, Eskola J, Leinonen M., Kayhty H, Nissinen A, Pekkanen E, Makela PH. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J. Infect. Dis. 1991:164:982–5
Taylor DN, Trofa AC, Sadoff J, Chu C., Bryla D, Shiloach J, Cohen D, Ashkenazi S, Lerman Y, Egan W, Schneerson R, Robbins JB. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a and Shigella sonnei (Plesiomonas shigelloides) bound to bacteria toxoids. Infect. Immun. 1994:61:3678–87.
Trollfors, B., J. Taranger, T. Lagergard, L. Lind, V Sundh, G. Zackrisson, W Blackwelder, C.U. Lowe and J. B. Robbins. 194. A double-blind, placebo-controlled trial of a monocomponent pertussis toxoid vaccine. Submitted for publication
Vann WF, Liu T-Y, Robbins JB. et al. Bacillus pumilus polysaccharide cross-reactive with meningococcal group A polysaccharide. Infect. Immun. 1976:13:1654–62.
van Wezel AL, van Steenis G, Hannik CA, Cohen H. New approach to the production of concentrated and purified inactivated polio and rabies tissue culture vaccines. Dev. Biol. Stand. 1978:41:159–168.
Vialard J, LaLumiere M., Vernet T. et al. Synthesis of the membrane fusion and hemagglutinin proteins of measles virus, using a novel baculovirus vector containing the β-galactosidase gene. J Virol. 1990:64:37–50.
Wagner DK, Clements ML, Reimer CB, Synder M., Nelson DL, Murphy BR. Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum. J. Clin. Microbiol. 1987:25:559–62.
Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog. Allergy. Karger S, Basel, 1969:13:1–110.
Watson DC, Robbins JB, and Szu SC, et al. Protection of mice against Salmonella typhimurium with an O-specific polysaccharide-protein vaccine. Infect. Immun. 1992:60:4679–86.
Weibel RE, Buynak EB, McLean AA, Roehm RR, Hilleman MR. Persistence of antibody in human subjects 7 to 10 years following administration of combined live attenuated measles, mumps and rubella virus vaccines. Proc. Soc. Exp. Biol. Med. 1980:165:260–3.
Wernet P, Breu H, Knop J, Rowley D. Antibacterial action of specific IgA and transport of IgM, IgA and IgG from serum into the small intestine. J. Infect. Dis. 1971:124:223–6.
Werzberger A, Mensch B, Kuter B. et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Eng J Med. 1993:327:453–7.
Wong KH, Barrera O, Sutton A. et al. Standardization and control of meningococcal vaccines, group A and group C polysaccharides. J. Biol. Stand. 1977:5:197–215.
World Health Organization Expert Committee on Biologic Standardization. Technical Report Series 840, 43rd Ed Geneva, Switzerland. Requirements on Vi polysaccharide for typhoid. 1993:14-32.
World Health Organization. Requirements for Haemophilus type b conjugate vaccines. WHO Technical Report Series, 1991:814.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Robbins, J.B., Schneerson, R., Szu, S.C. (1996). Hypothesis: How Licensed Vaccines Confer Protective Immunity. In: Cohen, S., Shafferman, A. (eds) Novel Strategies in the Design and Production of Vaccines. Advances in Experimental Medicine and Biology, vol 397. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-1382-1_22
Download citation
DOI: https://doi.org/10.1007/978-1-4899-1382-1_22
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-1384-5
Online ISBN: 978-1-4899-1382-1
eBook Packages: Springer Book Archive